A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

NCT04853251 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

188

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DEVICE: PDS Implant With Ranibizumab 100 mg/ml
DRUG: LUCENTIS (Ranibizumab Injection)

Sponsor

Genentech, Inc.